Will cancer metastasis occur while taking imatinib (Gleevec)?

Whether cancer metastasis will occur while taking Imatinib (Gleevec, Imatinib) depends on a variety of factors, including the patient's underlying condition, treatment compliance, and whether drug resistance occurs, etc. Imatinib is a tyrosine kinase inhibitor (TKI), mainly used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST< /span>), etc., its mechanism is to block the growth signals of cancer cells by inhibiting the BCR-ABL fusion gene or c-KIT mutant protein, thereby controlling tumor development. For most patients who receive early, standardized treatment, imatinib has a significant effect in controlling the disease.

However, in some cases, metastasis of cancer cells may still occur while taking imatinib. For example, if a patient's tumor is less sensitive to imatinib or develops resistance due to genetic mutations, the drug's efficacy may decrease, leading to disease progression or even distant metastasis. Especially in patients with solid tumors such as GIST, if the tumor has highly aggressive biological characteristics in the early stage, even if imatinib is used to control local lesions, it may still metastasize to the liver, peritoneum and other locations through the blood or lymphatic system.

In addition, if patients have problems such as irregular medication, interruption of treatment, or insufficient dosage, the therapeutic effect of imatinib may be greatly reduced, causing the originally controllable disease to relapse or spread. Therefore, during treatment, medications should be taken strictly in accordance with the doctor's instructions, and hematology and molecular biology monitoring should be performed regularly to ensure that the drug reaches therapeutic concentrations and to detect signs of drug resistance or disease progression as early as possible.

In short, imatinib can effectively delay disease progression and metastasis in most patients, but it cannot completely eliminate the possibility of cancer cell spread. Once signs of disease progression or metastasis are discovered during treatment, it is necessary to promptly evaluate whether there are drug-resistant mutations and consider adjusting the treatment plan, such as switching to second- or third-generation TKI drugs, or combining them with other treatments to improve treatment effects and survival rates.

Reference materials:https://www.gleevec.com/